eMedicine Specialties > Orthopedic Surgery > Neoplasms

Cartilage Tumors, Low Grade

Author: Anthony E Johnson, MD, Chief, Department of Specialty Care, Chief, Orthopaedic Surgery and Podiatry Service, Specialty Care, McDonald Army Hospital
Coauthor(s): Josefine M Heim-Hall, MD, Clinical Associate Professor, Department of Pathology, University of Texas Health Science Center at San Antonio; Ronald P Williams, MD, PhD, Chair, Department of Orthopedics, University of Texas Health Science Center at San Antonio
Contributor Information and Disclosures

Updated: May 8, 2008

Introduction

Cartilage tumors vary in severity from benign enchondroma to low-grade malignant chondrosarcoma to the highest-grade dedifferentiated chondrosarcoma. Chondrosarcoma is the second most common primary malignant bone tumor, accounting for 10-20% of all primary bony malignancies.1,2 Enchondroma, which consists of benign endosteal cartilage, is much more common than chondrosarcoma. The true incidence of cartilage tumors is unknown because many are discovered incidentally. Distinguishing benign cartilage tumors from low-grade malignant cartilage tumors is often challenging, but there are some established principles regarding location, size, and pain, as well as characteristics on radiography, computed tomography (CT), and magnetic resonance imaging (MRI).3,4,5,6,7

  • Location: Most cartilage tumors of the hands and feet are benign, whereas cartilage tumors of the pelvis, scapula, and sternum are more likely to be malignant.8
  • Size: Most enchondromas are smaller than 3 cm; benign tumors larger than 5 cm are uncommon.
  • Pain: Both benign and malignant cartilage tumors may be associated with pain. However, a careful history characterizing the pain may help distinguish pain due to arthrosis of an adjacent joint or other causes of limb pain from pain associated with an underlying bone lesion. If an injection in the adjacent joint completely relieves the pain, the associated bone lesion is a doubtful source of symptoms.
  • Radiographic features: Radiographs are crucial in distinguishing chondrosarcomas from enchondromas. Enchondromas are usually radiographically well marginated and are much more likely to demonstrate the characteristic punctate or flocculent intralesional mineralization pattern that is the hallmark of calcified hyaline cartilage. Enchondromas may also cause expansion of the cortex, especially in flat bones. More extensive endosteal erosion, especially involving greater than one half to two thirds the width of the cortex, should increase suspicion of malignancy, whereas frank cortical destruction and soft tissue extension should be considered evidence of malignancy.
  • Computed tomography: CT scanning is particularly useful in evaluating the relationship of an endosteal cartilage tumor to the adjacent cortex. An enchondroma is expected to have an intact rind of cortical bone surrounding it.9
  • Magnetic resonance imaging: MRI signal characteristics, such as increased signal intensity on T2-weighted images, heterogeneity of the matrix, and lack of intralesional mineralization, are suggestive of malignancy.

Even with optimal clinical, radiographic, and histologic data, there is often no clear distinction between benign and low-grade malignant cartilage tumors.1,10,11,12 This distinction is particularly difficult with very low grade chondrosarcomas, or so-called borderline chondrosarcomas. These cartilage tumors have cytology resembling enchondromas; cortical erosions or scalloping without frank full-thickness cortical destruction visible on plain radiographs; clinical presentation of intermittent to constant pain; and local recurrences similar to those of low-grade chondrosarcomas.13,14 Low-grade malignant chondrosarcomas, which constitute the majority of malignant cartilage tumors, have been described as having a slow growth rate, infrequent metastases, and a 90% 5-year survival rate.1,2,15

In addition to the conventional intramedullary tumors, both benign and malignant cartilage tumors may be found in periosteal locations or in soft tissue. Secondary chondrosarcomas may arise in an osteochondroma, in an enchondroma, or in the setting of enchondromatosis (Ollier disease or Maffucci syndrome) or multiple osteochondromatosis. The secondary chondrosarcomas are more likely to occur in patients with multiple cartilage tumors and typically present as a painful, progressively enlarging bony mass. Dedifferentiated chondrosarcoma is a distinct subgroup of chondrosarcoma in which a high-grade noncartilaginous sarcoma is adjacent to either a low-grade chondrosarcoma or enchondroma.

Lee et al monitored 227 patients with chondrosarcoma for an average of 6 years and reported predictive factors for metastasis to be local recurrence, pelvic location, tumor volume greater than 100 cc, aneuploidy of the tumor coupled with a high mean DNA index, histologic grade 3, and dedifferentiated chondrosarcomas. The reported recurrence rate ranges from 4-12%, depending on initial treatment modality and tumor grade.16,17

Classically, because chondrosarcomas are known to be resistant to radiotherapy and chemotherapy, wide resection has generally been accepted as recommended treatment for low-grade chondrosarcoma.18,19,20,21 Borderline cartilage tumors have an even lower metastatic potential than the true low-grade (grade 1) malignant chondrosarcoma.9,13 Thus, recommended treatment of these borderline tumors has ranged from marginal curettage and grafting to limited local resection. There has been a push for more conservative treatment of borderline and low-grade malignant chondrosarcomas, with extended intralesional curettage being considered a viable alternative to wide resection.9,13,14

Related Medscape topics:
Specialty Site Orthopaedics
Specialty Site Oncology
Resource Center Cancer: Biologic Therapies
Metastases or Osteoma?

Case Studies

The following discussion is a description of 2 cases that initially presented as clinically, radiographically, and pathologically borderline cartilage tumors and eventually demonstrated aggressive metastatic behavior, as well as a third case in which a radiographically and histologically benign enchondroma was detected only after it had undergone dedifferentiation into a high-grade osteosarcoma and resulted in a pathologic fracture. Case 1

A 38-year-old female athlete presented with a minimally painful lump on the medial side of her left knee (see Image 1). She underwent open biopsy with curettage later that same month. Histology at that time showed benign enchondroma with focal atypia (see Image 2). The patient developed a recurrence of the mass 19 months later. She underwent augmented (phenol) marginal resection 2 months after the recurrence, after refusing wide resection. Histology showed progression from a purely low-grade to a mixed low- and intermediate-grade lesion (ie, chondrosarcoma grade 1-2 of 3 [see Image 3]).

One year after the first recurrence, she developed a second recurrence and underwent wide resection and reconstruction of the distal femur. The tumor within the distal femur was a high-grade dedifferentiated chondrosarcoma with osteosarcomatous features (see Image 4). She then underwent adjuvant chemotherapy for osteosarcoma.

Five months after the second recurrence, she developed lung metastases. Biopsy of the lung lesions revealed dedifferentiated chondrosarcoma. One month later, she developed a recurrence of the high-grade sarcoma in the popliteal fossa. The patient underwent above-knee amputation and died of progression of the lung metastases 1 year later.

Case 2

A 39-year-old man presented with anterior bowing of his right femur and a leg-length discrepancy. At age 16 years, he had undergone an osteotomy to correct the angular deformity. Plain radiography of the right distal femur revealed a cartilage tumor in the distal femur. MRI demonstrated disruption of the anterior femoral cortex, with thinning of the articular cartilage. The patient underwent curettage and bone grafting. Histologic examination revealed a well-differentiated cartilaginous tumor, and a diagnosis of benign enchondroma was favored (see Image 5). The original osteotomy was apparently through the enchondroma (see Image 6).

The patient reported recurrent knee pain 20 months after curettage and bone grafting and underwent repeat curettage. The histology showed progression to grade 2 chondrosarcoma (see Image 7). Follow-up CT scan showed a lytic lesion in the posterior femoral condyle extending to the distal femoral joint line. He underwent wide resection with distal femoral replacement 2 months later. The histologic examination confirmed grade 2 chondrosarcoma.

Thirteen months later, CT scanning of the chest revealed approximately 20 small pulmonary nodules. The resected lung nodules all revealed grade 2 chondrosarcoma histologically identical to the tumor excised from the distal femur (see Image 8). The patient initiated chemotherapy. Six months later, he had multiple enlarging nodules but remained asymptomatic, and he refused further treatment.

Case 3

A 70-year-old man sustained a right supracondylar femur fracture after stepping out of the bathtub. Incisional biopsy of the fracture site was performed. Histologic examination revealed a high-grade osteosarcoma with soft tissue extension sharply juxtaposed to an enchondroma (see Image 9). He underwent right hip disarticulation 1 week later. He declined chemotherapy. Lung nodules appeared on chest radiography 2 months postoperatively. CT scanning confirmed the presence of multiple pulmonary nodules consistent with metastases.

Discussion

Differentiation of benign active and low-grade (grade 1) malignant cartilaginous lesions is difficult. Recent diagnostic schemata have included a borderline category of cartilage tumors.13,14 Some authors have supported a more conservative intralesional curettage with or without surgical adjuvant therapy (such as liquid nitrogen or phenol) as effective therapy for these borderline tumors. Although the overall recurrence rate of low-grade chondrosarcoma is low, a substantial proportion of the recurrent tumors manifest themselves at a higher histologic grade than their corresponding primary tumors. The reported frequency of this recurrence varies in the literature but may be as high as 61%.17

Case 1 and Case 2 are examples of grade progression from a borderline tumor to a grade 2 chondrosarcoma. Both patients underwent limited resection of their original borderline chondrosarcomas, but the disease recurred as higher-grade tumors at 19 and 20 months from initial presentation, respectively. The patient in Case 1 refused wide resection at recurrence and eventually developed lung metastases after dedifferentiation at the primary site. Whether this poor outcome could have been prevented with wide resection of the recurrent tumor is unknown. The patient in Case 2, on the other hand, did undergo wide resection of recurrent tumor, but metastasis occurred nevertheless. Although both cases underscore the need for wide resection of the recurrent chondrosarcoma, the second case questions the safety of conservative management for borderline chondrosarcoma.

Case 3 is an example of what appeared to be a solitary benign enchondroma that dedifferentiated into a high-grade osteosarcoma. This is a rare event, with only a few cases reported in the literature.22 Although wide excision would not be the recommended treatment for a benign enchondroma, this case serves as another example of an unusually aggressive cartilage tumor.

Conclusion

Currently, no prospective, controlled studies describe the appropriate treatment for borderline or low-grade (grade 1) malignant chondrosarcomas. Some authors have suggested that extended intralesional curettage may be acceptable for both types. However, limited resection was clearly insufficient to control borderline cartilage tumors in the case studies described above and resulted in an unexpectedly poor outcome. Caution should be utilized both in making the distinction between benign and malignant cartilage tumors and in selecting the appropriate surgical treatment for grade I chondrosarcomas.

Multimedia

Original MRI of a patient demonstrating a lesion ...Media file 1: Original MRI of a patient demonstrating a lesion extending beyond the boundary of normal bone.
Original MRI of a patient demonstrating a lesion ...

Original MRI of a patient demonstrating a lesion extending beyond the boundary of normal bone.

Histology of original lesion demonstrating what w...Media file 2: Histology of original lesion demonstrating what was thought to be a benign enchondroma with some atypical features.
Histology of original lesion demonstrating what w...

Histology of original lesion demonstrating what was thought to be a benign enchondroma with some atypical features.

Recurrent tumor demonstrating progression from a ...Media file 3: Recurrent tumor demonstrating progression from a purely low-grade lesion to a mixed low- and intermediate-grade lesion.
Recurrent tumor demonstrating progression from a ...

Recurrent tumor demonstrating progression from a purely low-grade lesion to a mixed low- and intermediate-grade lesion.

Tumor from distal femur at time of reconstruction...Media file 4: Tumor from distal femur at time of reconstruction demonstrating dedifferentiated chondrosarcoma.
Tumor from distal femur at time of reconstruction...

Tumor from distal femur at time of reconstruction demonstrating dedifferentiated chondrosarcoma.

Tumor from pin sites revealing a well-differentia...Media file 5: Tumor from pin sites revealing a well-differentiated cartilaginous tumor. The diagnosis of benign enchondroma was favored at this point.
Tumor from pin sites revealing a well-differentia...

Tumor from pin sites revealing a well-differentiated cartilaginous tumor. The diagnosis of benign enchondroma was favored at this point.

AP radiograph of the knee demonstrating a tumor a...Media file 6: AP radiograph of the knee demonstrating a tumor around screw holes.
AP radiograph of the knee demonstrating a tumor a...

AP radiograph of the knee demonstrating a tumor around screw holes.

Histology at time of recurrence showing progressi...Media file 7: Histology at time of recurrence showing progression to grade 2 chondrosarcoma.
Histology at time of recurrence showing progressi...

Histology at time of recurrence showing progression to grade 2 chondrosarcoma.

Histology showing grade 2 chondrosarcoma within l...Media file 8: Histology showing grade 2 chondrosarcoma within lung metastases. This tumor was identical to the tumor resected from the distal femur.
Histology showing grade 2 chondrosarcoma within l...

Histology showing grade 2 chondrosarcoma within lung metastases. This tumor was identical to the tumor resected from the distal femur.

Histology at fracture site demonstrating sharp ju...Media file 9: Histology at fracture site demonstrating sharp juxtaposition of benign enchondroma with osteosarcoma.
Histology at fracture site demonstrating sharp ju...

Histology at fracture site demonstrating sharp juxtaposition of benign enchondroma with osteosarcoma.

This patient has an enchondroma. Radiography typi...Media file 10: This patient has an enchondroma. Radiography typically shows well-defined, sharply marginated medullary lesions, often with punctate ring and arclike calcifications. Bone infarcts may appear similar to enchondromata on plain radiography. CT scanning is recommended to evaluate the extent of endosteal scalloping.
This patient has an enchondroma. Radiography typi...

This patient has an enchondroma. Radiography typically shows well-defined, sharply marginated medullary lesions, often with punctate ring and arclike calcifications. Bone infarcts may appear similar to enchondromata on plain radiography. CT scanning is recommended to evaluate the extent of endosteal scalloping.

This patient has a chondrosarcoma. The MRI demons...Media file 11: This patient has a chondrosarcoma. The MRI demonstrates a lesion in the proximal humerus, with extension through the cortex into the soft tissues. The distinction between enchondroma and chondrosarcoma is extremely difficult, even with complete radiographic and histopathologic evaluation.
This patient has a chondrosarcoma. The MRI demons...

This patient has a chondrosarcoma. The MRI demonstrates a lesion in the proximal humerus, with extension through the cortex into the soft tissues. The distinction between enchondroma and chondrosarcoma is extremely difficult, even with complete radiographic and histopathologic evaluation.

Keywords

chondrosarcomas, enchondromas, osteosarcoma, multiple enchondromatosis, Ollier disease, Ollier's disease

 


More on Cartilage Tumors, Low Grade

References

References

  1. Healey JH, Lane JM. Chondrosarcoma. Clin Orthop Relat Res. Mar 1986;119-29. [Medline].

  2. Rizzo M, Ghert MA, Harrelson JM. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. Oct 2001;224-33. [Medline].

  3. Altay M, Bayrakci K, Yildiz Y, Erekul S, Saglik Y. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci. Sep 2007;12(5):415-23. [Medline].

  4. Ryzewicz M, Manaster BJ, Naar E, Lindeque B. Low-grade cartilage tumors: diagnosis and treatment. Orthopedics. Jan 2007;30(1):35-46; quiz 47-8. [Medline].

  5. O'Connor MI, Bancroft LW. Benign and malignant cartilage tumors of the hand. Hand Clin. Aug 2004;20(3):317-23, vi. [Medline].

  6. Gajewski DA, Burnette JB, Murphey MD, Temple HT. Differentiating clinical and radiographic features of enchondroma and secondary chondrosarcoma in the foot. Foot Ankle Int. Apr 2006;27(4):240-4. [Medline].

  7. Chow WA. Update on chondrosarcomas. Curr Opin Oncol. Jul 2007;19(4):371-6. [Medline].

  8. Unni KK. Chondrosarcoma (primary, secondary, dedifferentiated, and clear cell). In: Dahlina's Bone Tumors. General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia, Pa: Lippincott-Raven;1996: 71-108.

  9. Springfield DS, Gebhardt MC, McGuire MH. Chondrosarcoma: a review. Instr Course Lect. 1996;45:417-24. [Medline].

  10. Crim JR, Seeger LL. Diagnosis of low-grade chondrosarcoma. Radiology. Nov 1993;189(2):503; discussion 504. [Medline].

  11. Eriksson AI, Schiller A, Mankin HJ. The management of chondrosarcoma of bone. Clin Orthop Relat Res. Nov-Dec 1980;44-66. [Medline].

  12. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. May 1996;78(5):656-63. [Medline].

  13. Tsuchiya H, Ueda Y, Morishita H. Borderline chondrosarcoma of long and flat bones. J Cancer Res Clin Oncol. 1993;119(6):363-8. [Medline].

  14. Yasko AW. Treatment of low-grade chondrosarcoma. Curr Opin Orthop. 2000;11:471-8.

  15. Weber KL, Pring ME, Sim FH. Treatment and outcome of recurrent pelvic chondrosarcoma. Clin Orthop Relat Res. Apr 2002;19-28. [Medline].

  16. Bauer HC, Brosjo O, Kreicbergs A. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand. Jun 1995;66(3):283-8. [Medline].

  17. Carsi B, Sim FH. Recurrent classic chondrosarcoma of the extremities. J Bone Joint Surg. 2001;83-B Suppl:164.

  18. Harwood AR, Krajbich JI, Fornasier VL. Radiotherapy of chondrosarcoma of bone. Cancer. Jun 1 1980;45(11):2769-77. [Medline].

  19. Lack W, Lang S, Brand G. Necrotizing effect of phenol on normal tissues and on tumors. A study on postoperative and cadaver specimens. Acta Orthop Scand. Jun 1994;65(3):351-4. [Medline].

  20. Lee FY, Mankin HJ, Fondren G. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. Mar 1999;81(3):326-38. [Medline].

  21. McNaney D, Lindberg RD, Ayala AG. Fifteen year radiotherapy experience with chondrosarcoma of bone. Int J Radiat Oncol Biol Phys. Feb 1982;8(2):187-90. [Medline].

  22. Smith GD, Chalmers J, McQueen MM. Osteosarcoma arising in relation to an enchondroma. A report of three cases. J Bone Joint Surg Br. Mar 1986;68(2):315-9. [Medline].

Further Reading

Keywords

chondrosarcomas, enchondromas, osteosarcoma, multiple enchondromatosis, Ollier disease, Ollier's disease

Contributor Information and Disclosures

Author

Anthony E Johnson, MD, Chief, Department of Specialty Care, Chief, Orthopaedic Surgery and Podiatry Service, Specialty Care, McDonald Army Hospital
Anthony E Johnson, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, Society of Military Orthopaedic Surgeons, and Western Orthopaedic Association
Disclosure: Nothing to disclose.

Coauthor(s)

Josefine M Heim-Hall, MD, Clinical Associate Professor, Department of Pathology, University of Texas Health Science Center at San Antonio
Josefine M Heim-Hall, MD is a member of the following medical societies: Children's Oncology Group, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Ronald P Williams, MD, PhD, Chair, Department of Orthopedics, University of Texas Health Science Center at San Antonio
Ronald P Williams, MD, PhD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American College of Surgeons, American Medical Association, American Orthopaedic Association, American Society for Bone and Mineral Research, Clinical Orthopaedic Society, Mid-America Orthopaedic Association, Musculoskeletal Tumor Society, Orthopaedic Research Society, Southwestern Oncology Group, Texas Medical Association, and Texas Orthopaedic Association
Disclosure: Nothing to disclose.

Medical Editor

Timothy A Damron, MD, David G Murray Endowed Professor, Department of Orthopedic Surgery, Professor, Orthopedic Oncology and Adult Reconstruction, Vice Chair, Department of Orthopedics, State University of New York Upstate Medical University at Syracuse
Timothy A Damron, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American College of Surgeons, American Medical Association, Children's Oncology Group, Connective Tissue Oncology Society, Musculoskeletal Tumor Society, Orthopaedic Research Society, and Society for Experimental Biology and Medicine
Disclosure: Lippincott, Williams, and Wilkins Royalty Editing/writing textbook; Genentech Grant/research funds Clinical research; Orthovita Grant/research funds Clinical research; National Institutes of Health Grant/research funds Clinical research

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Ian D Dickey, MD, FRCSC, Adjunct Professor, Department of Chemical and Biological Engineering, University of Maine; Consulting Staff, Adult Reconstruction, Orthopedic Oncology, Department of Orthopedics, Eastern Maine Medical Center
Ian D Dickey, MD, FRCSC is a member of the following medical societies: American Academy of Orthopaedic Surgeons, British Columbia Medical Association, Canadian Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Stryker Orthopaedics Consulting fee Consulting

CME Editor

Dinesh Patel, MD, FACS, Associate Clinical Professor of Orthopedic Surgery, Harvard Medical School; Chief of Arthroscopic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital
Dinesh Patel, MD, FACS is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Association of Physicians of Indian Origin, American College of International Physicians, and American College of Surgeons
Disclosure: Nothing to disclose.

Chief Editor

Harris Gellman, MD, Consulting Surgeon, Broward Hand Center, Voluntary Clinical Professor of Orthopedic Surgery and Plastic Surgery, Departments of Orthopedic Surgery and Surgery, University of Miami School of Medicine
Harris Gellman, MD is a member of the following medical societies: American Academy of Medical Acupuncture, American Academy of Orthopaedic Surgeons, American Orthopaedic Association, American Society for Surgery of the Hand, and Arkansas Medical Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.